IHC - Final diagnostic panel; Non Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma (NHL) is a complex group of malignancies that vary in their behavior and response to treatment. They stem from cells of the lymphatic system, an essential part of the body's immune system. The diagnosis, classification, and appropriate therapeutic approach for NHL require specific testing, including the use of immunohistochemistry (IHC). IHC is an invaluable technique in pathology that utilizes antibodies to detect specific proteins in the cells of a tissue sample, helping to define the exact type of NHL.
Profile Name IHC - Final diagnostic panel; Non Hodgkin's Lymphoma
Sample Type Tissue
Preparations Required None. The test is performed on a tissue sample collected via biopsy.
Report Time 5 days
This IHC diagnostic panel for NHL encompasses an array of markers, which are chosen reflexively based on the tumor's morphological characteristics. These markers include LCA, CD20, CD79a, PAX5, CD3, CD5, CD4, CD8, CD7, CD25, CD123, Oct2, BOB1, MUM-1, Bcl2, Bcl6, CD10, CD23, CD138, kappa, lambda, CD56, CD57, CD68, CD138, CD15, CD30, TdT, CD99, MPO, CD117, Granzyme B, cyclin D1, EBV, CD2, ALK-1, Perforin, TIA1, and Langerin.
Home Sample Collection Process
1
Book your convenient slot
2
Sample Collection by Phlebotomist
3
Reporting of the sample at lab
4
Download Reports
Note: Home Sample Collection is only for Pathology lab tests.
Frequently Asked Questions
This test is critical for diagnosing and classifying Non-Hodgkin's Lymphoma, which is essential for
planning the appropriate treatment strategy.
No, fasting is not required for this test as it is performed on a tissue sample collected via biopsy.
This test uses specific antibodies to identify different proteins in a tissue sample. These proteins can
provide important information about the subtype of Non-Hodgkin's Lymphoma.
Your doctor will recommend this test if they suspect you have Non-Hodgkin's Lymphoma based on symptoms,
clinical findings, and other diagnostic tests.
This test is typically done once to diagnose and classify Non-Hodgkin's Lymphoma. However, it may be
repeated if needed, for example, in the event of a relapse.
As this test aims to identify specific proteins in the cells, it does not have standard "normal" values.
The results are interpreted by a pathologist based on the presence or absence of these proteins.
There are no specific precautions needed for this test. Follow your healthcare provider's instructions
regarding the biopsy procedure.
The expression of these proteins can be influenced by the subtype of Non-Hodgkin's Lymphoma and the
particular genetic mutations within the cancer cells.
Abnormal results should be discussed with your oncologist or hematologist who can guide you through the
next steps in your treatment plan.
No, the test results depend on the presence of certain proteins indicative of Non-Hodgkin's Lymphoma, not
the age or gender of the patient.
No specific preparation is needed for this test. It is performed on a tissue sample usually obtained
through a biopsy procedure.
This test can identify a wide range of Non-Hodgkin's Lymphoma subtypes. However, additional tests may be
required for a complete diagnosis and classification.
If the results are inconclusive, your doctor may recommend additional testing or repeat the biopsy
procedure to obtain a new sample.
No, the results of this test are not influenced by lifestyle factors. They are a reflection of the
underlying disease process.
The biopsy procedure involves taking a small tissue sample from the suspected area. This procedure is
usually performed under local or general anesthesia.
Understanding the type of Non-Hodgkin's Lymphoma is vital for determining the most effective treatment plan. The IHC final diagnostic panel is a sophisticated tool that aids healthcare professionals in diagnosing and classifying NHL, leading to more personalized and targeted treatment strategies. Always discuss the test results with your healthcare provider to understand the implications for your treatment plan and overall health.
